In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors :: Grohs P
Taieb G
Morand P
Kaibi I
Podglajen I
Lavollay M
Mainardi JL
Compain F
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Mar 24; Vol. 61 (4). Date of Electronic Publication: 2017 Mar 24 (Print Publication: 2017).
Publication Year :: 2017
Abstract: Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa , 11 Achromobacter xylosoxydans , and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%).<br /> (Copyright © 2017 American Society for Microbiology.)

Subjects :: Achromobacter denitrificans drug effects
Ceftazidime pharmacology
Cystic Fibrosis microbiology
Drug Resistance, Multiple, Bacterial genetics
Gram-Negative Bacteria drug effects
Humans
Meropenem
Microbial Sensitivity Tests
Penicillanic Acid analogs & derivatives
Penicillanic Acid pharmacology
Piperacillin pharmacology
Piperacillin, Tazobactam Drug Combination
Pseudomonas aeruginosa drug effects
Stenotrophomonas maltophilia drug effects
Tazobactam
Thienamycins pharmacology
Anti-Bacterial Agents pharmacology
Cephalosporins pharmacology

Full Text Access

Tools